about
Towards Stratified Medicine in Plasma Cell MyelomaAdvances in understanding prognosis in myeloma.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).Primary Plasma Cell Leukemia: Identity Card 2016.Current Review on High-Risk Multiple Myeloma.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testingPomalidomide in the treatment of multiple myeloma: design, development and place in therapy.Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.The effect of novel therapies in high-molecular-risk multiple myeloma.Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT.Nanotherapeutics for multiple myeloma.Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPReal-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
P2860
Q28074994-F29E1894-AB7C-47E5-B2B8-50172E56E947Q30244061-2F05C12D-B1DF-4839-9561-4B97BACF1749Q31154933-870812BA-5F37-49DC-894D-BF0D4F3A7CE1Q33430690-CE2CEC53-7F39-403D-9B6F-C90E25FB9330Q38714809-252AB2C9-CF93-4B75-8DAE-D18BC851D6CFQ38781794-AECD7259-66D4-444F-B74A-F40455130D28Q38895167-ED6AE84B-357E-4CA4-93B6-9207724C04A5Q38932298-9DE688BD-5CD8-4C23-AFEE-1944C9B2E0B4Q39518931-A283130C-6A61-4BDE-8154-6B51B486A0D7Q41346803-7819AAD6-6F1F-44AF-966E-4D4D384433A9Q41545464-8E7FAA3C-C475-4112-8F3A-3A105C36A5A1Q46640442-29F302D7-EDA9-4017-96D0-7CDCC8A9666EQ47375990-3FF48622-E6AD-454A-B337-27C3C722437FQ50057730-B9C7AFE8-D7C6-4046-BB94-79415FCFA4B0Q50118881-C8D595CE-4039-4F94-942F-F0195F591919Q52559684-40208878-C758-45C2-B530-A0E5E2413F48Q52609413-1F5E9CD5-B34A-41EC-861E-7B72B76B6FE5Q52663601-247F716A-4310-44FA-9C21-9E97943E6B0C
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Defining and treating high-risk multiple myeloma.
@en
type
label
Defining and treating high-risk multiple myeloma.
@en
prefLabel
Defining and treating high-risk multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
Defining and treating high-risk multiple myeloma.
@en
P2093
J S Miguel
M-V Mateos
P Rodriguez-Otero
S Z Usmani
P2860
P2888
P304
P356
10.1038/LEU.2015.209
P577
2015-08-12T00:00:00Z
P6179
1018475875